• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Veracyte Inc (NQ: VCYT )

    33.74 -1.26 (-3.60%)
    Official Closing Price Updated: 4:15 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Veracyte Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
    From Veracyte, Inc.
    Via Business Wire
    Breaking Down Veracyte: 4 Analysts Share Their Views
    Via Benzinga
    New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
    From Veracyte, Inc.
    Via Business Wire
    A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
    Via Benzinga
    Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
    A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
    Via Investor's Business Daily
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
    From Veracyte, Inc.
    Via Business Wire
    Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
    Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
    Via Investor's Business Daily
    Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
    Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
    Via Benzinga
    Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
    Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher... 
    Via Benzinga
    Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
    Via InvestorPlace
    VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024
    VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Veracyte Announces Second Quarter 2024 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    The 3 Best Personalized Nutrition Stocks to Buy Now
    Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
    From Veracyte, Inc.
    Via Business Wire
    Trading SMID Biotech Stocks In A Volatile Market
    Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
    Via Talk Markets
    Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
    On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
    Via Benzinga
    Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024
    VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Veracyte Announces First Quarter 2024 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
    From Veracyte, Inc.
    Via Business Wire
    New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
    From Veracyte, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.